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A B S T R A C T
Introduction. The goal of testosterone replacement is to provide long-term physiological supplementation at
sufficient levels to mitigate the symptoms of hypogonadism.
Aim. The objective of this work is to determine if the implantable nanochannel delivery system (nDS) can present
an alternative delivery strategy for the long-term sustained and constant release of testosterone.
Methods. A formulation of common testosterone esters (F1) was developed to enable nanochannel delivery of the
low water soluble hormone. In vivo evaluation of testosterone, luteinizing hormone (LH) and follicle stimulating
hormone (FSH) levels by liquid chromatography/mass spectrometry and a multiplex assay, respectively, in castrated
Sprague-Dawley rats implanted with nDS-F1 implants or polymeric pellets was performed over a 6-month period.
The percent of testosterone concentrations observed that fell within the normal range of testosterone levels for each
animal was calculated and used to compare the study groups.
Main Outcome Measures. Sustain release of testosterone in vivo for over 6 months.
Results. The subcutaneous release of F1 from nDS implants exhibited sustained in vivo release kinetics and attained
stable clinically relevant plasma testosterone levels. Plasma LH and FSH levels were significantly diminished in
nDS-F1 implant–treated animals, confirming biological activity of the released testosterone.
Conclusions. In conclusion, we demonstrate that nDS-F1 implants represents a novel approach for the treatment of
male hypogonadism. Further studies will be performed in view of translating the technology to clinical use. Ferrati
S, Nicolov E, Zabre E, Geninatti T, Shirkey BA, Hudson L, Hosali S, Crawley M, Khera M, Palapattu G, and
Grattoni A. The nanochannel delivery system for constant testosterone replacement therapy. J Sex Med
2015;12:1375–1380.
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Introduction
Hypogonadism in men is defined as belownormal testosterone plasma levels associated
with symptoms such as: loss of lean muscle mass,
erectile dysfunction, loss of libido, weight gain,
infertility, depressed mood, and osteoporosis [1].
Testosterone replacement therapy (TRT) is the
standard of care currently used to treat hypogo-
nadism [2]. Some of these therapies include:
patches, gels, solutions, depot injections, and
implantable polymeric pellets [3–6]. Although
commonly used, these therapies still suffer from1Co-senior authors.
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limitations that impact patient quality of life. For
instance, gels, and patches, although easy to self-
administer, require daily administration and can
easily expose individuals in contact with the
patient to excess amounts of testosterone. Injec-
tions can be used to overcome these limitations.
However, the pharmacokinetic profile of inject-
able testosterone is not optimal given the initial
burst in testosterone levels observed that is fol-
lowed by a decrease to subtherapeutic levels before
the next dose. Notably, polymeric implantable tes-
tosterone pellets slowly release testosterone over
the course of several months; however, they
exhibit typical polymer release kinetics that are
initially too high and finally too low.
A delivery system capable of providing con-
stant, long-term, and sustained testosterone
release would markedly improve treatment
options for postpubertal males suffering from
androgen deficiency leading to hypogonadism. In
prior work, we used our nanochannel delivery
system (nDS) [7,8] to achieve long-term and sus-
tained release of several drugs including letrozole,
growth hormone, leuprolide, and interferon
gamma, and nanoparticles [9] among others.
Extensive description and characterization of the
device can be found on previous publications [10].
Briefly, the platform leverages a silicon membrane
presenting 105 ∼ 107 identical, geometrically
defined nanochannels that control the rate of drug
release by physico-electrostatic confinement
[11,12]. The constant release is achieved by tailor-
ing the nanochannel size to each specific drug
molecule to allow passive constrain of molecular
diffusion thus achieving constant release rates. By
altering the number of nanochannels, nDS can be
customized to vary the dose according to target
daily delivery rates. The membrane is attached to
an implantable titanium or polyether ether ketone
plastic reservoir with medical grade UV cured
epoxy [7]. The device does not require moving
components or power source for its operation. It
does not suffer from decaying release profiles as it
is not affected by the amount of drug loaded in the
reservoir up to ∼90% of the released amount. The
device can be easily used for the release of a broad
spectrum of drugs, rendering it a potential flexible
and versatile tool for clinical applications [7].
In the study reported here, we optimized the
nDS for the long-term and sustained release of
testosterone formulations in preclinical models.
The goal was to restore rat’s physiological sys-
temic concentrations of testosterone in castrated
animals.
Material and Methods
Nanochannel membranes were attached to Gr2
titanium reservoirs (NanoMedical Systems, Austin,
TX, USA) with medical grade epoxy (OG116-31,
Epoxy Technology, Inc., Billerica, MA, USA) and
cured by UV light. Nanochannel membrane and
assembly are described in detail elsewhere [13].
Testosterone formulation (∼500 mg) or phosphate
buffer control were loaded into the device. The
amounts loaded were calculated for release treat-
ments expected to last for about 6 months. The in
vivo study was carried out according to the
approved protocol (AUP-0411-0018) from the
Institutional Animal Care and Use Committee
(IACUC) of The Houston Methodist Research
Institute. Castrated male Sprague-Dawley (SD)
rats (Harlan Laboratories, Indianapolis, IN, USA)
were randomized into three groups (n = 6–12): (i)
nDS implant loaded with a testosterone esters for-
mulation (nDS-F1 implants); (ii) implant loaded
with phosphate buffered saline 1X, pH 7.2 (nDS-
PBS implants); and (iii) 25 mgTestopel® testoster-
one polymeric pellets (TPPs). Intact, noncastrated
rats were used as controls (n = 6). Nanochannel
implants and degradable pellets were subcutane-
ously inserted in the dorsum of anesthetized
animals. Standard postsurgical animal carewas pro-
vided for up to 48 h postsurgery. Blood samples
were collected at different time points from the
saphenous vein. Plasma was separated at 5,000 × g
for 10 minutes.
Plasma testosterone concentrations were mea-
sured with mass spectrometry with an optimized
protocol described in detail elsewhere [14]. For
each animal, data were analyzed by calculating the
percentage of observed concentrations that fell
within the normal range of testosterone levels in
plasma for rats and comparing the study groups
(Figure 1A, table). The normal physiological range
for rats was based on data from seven previously
published studies [15,16]. Some of these studies
reported the minimum and maximum plasma level
values. For those studies inwhich theminimumand
maximum values were not indicated, the values
were calculated by subtracting/adding two standard
deviations to the reported mean. The minimum
(50 ng/dL) and the maximum (950 ng/dL) were
used to define the normal testosterone range for
rats. Eachmeasured concentration was categorized
as within or not within the normal range. The
percentage of observations within range was calcu-
lated for each animal throughout all the time points
and averaged across the animals in each study group
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Figure 1 Picture: nDS membrane and titanium implants, and 3D rendering of the implant structure; Graph: Testosterone
concentration in plasma from noncastrated rats (control, n = 6), and castrated rats implanted with either: nDS-PBS implants
(negative control, n = 6); nDS-F1 implants (n = 14); or testosterone polymeric pellets (TPP) (n = 6). Values were corrected for
animal weight differences during the experiment. Note that the y-axis is noncontinuous, and the scale in the bottom section
has been modified for clarity. The blue-shaded region represents normal testosterone physiologic range in plasma in rats.
Table: Summary statistics of the percentage of observations in each study group where testosterone was in the normal range
(0.5 × 102 to 9.5 × 102 ng/dl). Average, lowest and highest percentages are reported. t-Tests were used to compare the
percentage of observations in normal range between study groups. Averages followed by “*” are significantly different and
by “∧” are not significantly different (P = 0.05) (SD: standard deviation) (A). Plasma LH and FSH levels obtained from all
animal groups. Some castrated rats had LH beyond the range of the standard curve, hence, they were considered to be at
the highest standard concentration (30 × 102 ng/dl) (B–C). Error bars represent the standard deviation (A–C).
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(average%). The lowest and highest percentage for
each study group was also reported. t-Tests were
used to compare the percentage of observations in
normal range between nDS-F1 implant and TPP
groups, and nDS-F1 implant and intact groups.
Analysis of luteinizing hormone (LH) and follicle
stimulating hormone (FSH) plasma levels was per-
formed at the Ligand Core (University of Virginia,
VA, USA) with the Millipore Multiplex Endocrine
Assay (Millipore, Billerica,MA,USA). At the endof
the study, a necropsy was performed removing the
implant and collecting tissue for histology. Tissue
sections were collected from the implanted site
(skin layer above exit port or in proximity of the
implanted pellet) and from a nonimplanted site
(least 1 cm away from the implantation site). His-
tological analysis including sample preparation and
scoringwas performed in the PathologyCore at the
Houston Methodist Research Institute.
Results
Toenable the otherwise poorly soluble testosterone
to be delivered by nDS within the aqueous subcu-
taneous in vivo environment, a testosterone ester
formulation (F1) was developed with an excipient
content lower than 20%, and the release of F1 from
nDS implants and bioactivity was studied in vivo.
Titanium implants (Figure 1A, picture) assembled
with the optimally sized nanochannel membrane,
as determined through in vitro testing, were loaded
with F1. PBS loaded nDS implants were used as
negative controls, whereas TPPs, the conventional
treatment, were used as positive control. Devices
and TPPs were subcutaneously implanted in the
dorsum of 2-month-old male castrated SD rats. All
animals were treated per the approved protocol
(AUP-0411-0018) from the IACUC of the
Houston Methodist Research Institute. Testoster-
one levels were monitored on days 0, 1, 2, 8 and
thenweekly throughout the experiment bymeasur-
ing testosterone concentration in plasma samples
by LC/MS. Figure 1A reports the plot of plasma
concentrations vs. time. Total testosterone levels in
castrated rats implanted with nDS-F1 implants
were constant and sustained for up to 182 days
(Figure 1A, graph) with an average concentration
of testosterone of 380 ng/dL ± 493. Noncastrated
rats showed an average testosterone concentration
of 180 ng/dL ± 164, whereas nDS-PBS implants,
used as negative control, showed testosterone levels
always close or equal to zero.
At the end of the study, tissue samples from
implanted animals were processed for histopathol-
ogy. Samples taken both at the exit port of the
implant and 1 cm away from the implant site were
analyzed by a blinded pathologist and scored for
fibrosis and inflammation. Fibrosis and mild
inflammation were found near the exit ports in the
tissue of all animals implanted with nDS-F1
(Figure 2, table and C) and near TPP implantation
site (Figure 2, table) as compared with normal
tissues (Figure 2, table and B).
The levels of LHandFSHdetermined in plasma
by a multiplex assay, indicated that the testosterone
released through nDS was still biologically active
[2,17]. All castrated rats showed baseline levels of
LHandFSHseveral folds higher thannoncastrated
rats (Figure 1B, C); with an average of 2,120
(±500.38) ng/dL vs. 138 (±49) ng/dL for LH
Figure 2 Histopathology results: His-
tology scoring of tissue collected from
noncastrated rats and castrated rats
implanted with either: nDS-F1 implants
or nDS-PBS implants or testosterone
polymeric pellets (TPPs) (SD: standard
deviation). 1Scale: Inflammation: 0,
none; 1, mild; 2, moderate; 3, marked.
Fibrosis: 0, 0%; 1, 25%; 2, 50%; 3,
75%; 4, 100%. 2Tissue samples col-
lected from the skin layer proximal to
the implant and at least 1 cm away from
the implant were paraffin embedded
and then stained for hematoxylin and
eosin stain (H&E) (A). H&E staining
micrographs: Subcutaneous tissue col-
lected from noncastrated control
animal (B) and from skin layer near
nDS-F1 implants exit port (C).
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and 6,800 (±1,869) ng/dL vs. 750 (±117) ng/dL
for FSH. Castrated animals implanted with PBS
also displayed significantly elevated levels of
LH (2,770 ± 1,062 ng/dL) and FSH (13,120 ±
6,540 ng/dL), for all the analyzed time points
(8, 35, 91, and 182 days). In contrast, in animals
treated with nDS-F1 implants and TPP, LH, and
FSH levels decreased on day 8 and reached
physiological levels (similar to noncastrated rats)
by day 35. Additionally, both LH and FSH levels
remained low up to day 91 in animals implanted
with nDS-F1 and lower than in animals
implanted with nDS-PBS and TPP until the end
of the experiment (day 182).
Discussion
Although the average concentration of testoster-
one in castrated rats implanted with nDS-F1
implants (380 ng/dL ± 493) was distinguishably
higher than the average concentration obtained in
intact, noncastrated rats (180 ng/dL ± 164), these
groups were not statistically different when the
percentage of observations that fell within the
range of normal testosterone levels were compared
by t-test (P = 0.05) (Figure 1A, table). This indi-
cates that the levels of testosterone released from
nDS implants in castrated rats were within the
physiological levels. As expected, castrated rats
implanted with nDS-PBS implants, scored the
lowest percentage of observations within the range
of normal testosterone levels (Figure 1A, graph
and table).
The observed fibrotic encapsulation and
inflammation near the implants and TPP
(Figure 2) are consistent with those found in lit-
erature for other implantable devices [18]. In
addition, despite the fibrotic encapsulation, tes-
tosterone release was not negatively affected.
This, combined with no adverse immune reaction
to the implants or abnormal wound healing, con-
firmed the biocompatibility and safety for the use
of the device in vivo, for long-term treatments.
In the context of their clinical use, it is foresee-
able that the devices will have transcutaneous
refill capabilities to minimize repeated implanta-
tion and explanation procedures.
LH and FSH levels (Figure 1B, C), two biologi-
cal indicators of testosterone function, correlate
well with the constantly sustained testosterone
plasma concentrations observed in nDS-F1
implant animals throughout the experiment and
the testosterone concentration decrease in TPP
animals after day 65 (Figure 1A).
Conclusion
In conclusion, we demonstrate that a testosterone
formulation (F1) can be successfully delivered via
our nDS implant in a constant manner for up to 6
months. These findings suggest that our nDS plat-
form may mitigate several key problems with
current TRT modalities and hence might repre-
sent an attractive alternative strategy for the long-
term treatment of male hypogonadism. In this
context, nDS implants may provide the optimal
platform technology for sustaining tight constant
levels of testosterone in the plasma while avoiding
the peak and trough in testosterone release asso-
ciated with currently adopted delivery modalities.
The implant may improve patient compliance and
quality of life by minimizing the need for frequent
dosing and plasma level adjustments. Additionally,
the nDS implant represents a flexible technology
that can be adapted for the controlled long-term
delivery [19] of a broad spectrum of therapeutics
for chronic pathologies. A limit of the system is
represented by the need of device explanation
which, however, could be overcome by adopting
transcutaneous refilling protocols.
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